|
|
Vaccine Detail
|
Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118 |
| Vaccine Information |
- Vaccine Name: Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007253
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- AR
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis and this vaccine has been used in early stage prostate cancer trials. (NCIT_C121777; Kyriakopoulos et al., 2020)
|
| Host Response |
|
|
| References |
Kyriakopoulos et al., 2020: Kyriakopoulos CE, Eickhoff JC, Ferrari AC, Schweizer MT, Wargowski E, Olson BM, McNeel DG. Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020; 26(19); 5162-5171. [PubMed: 32513836].
NCIT_C121777: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C121777]
|
|
